- Home
- PHUN vs MDXH Comparison
PHUN vs MDXH Comparison
Compare PHUN & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHUN
- MDXH
- Stock Information
- Founded
- PHUN 2009
- MDXH 2003
- Country
- PHUN United States
- MDXH Belgium
- Employees
- PHUN N/A
- MDXH N/A
- Industry
- PHUN EDP Services
- MDXH
- Sector
- PHUN Technology
- MDXH
- Exchange
- PHUN Nasdaq
- MDXH Nasdaq
- Market Cap
- PHUN 64.1M
- MDXH 84.6M
- IPO Year
- PHUN N/A
- MDXH 2021
- Fundamental
- Price
- PHUN $3.29
- MDXH $2.18
- Analyst Decision
- PHUN Buy
- MDXH Buy
- Analyst Count
- PHUN 2
- MDXH 1
- Target Price
- PHUN $7.75
- MDXH $6.00
- AVG Volume (30 Days)
- PHUN 280.4K
- MDXH 61.1K
- Earning Date
- PHUN 08-07-2025
- MDXH 08-20-2025
- Dividend Yield
- PHUN N/A
- MDXH N/A
- EPS Growth
- PHUN N/A
- MDXH N/A
- EPS
- PHUN N/A
- MDXH N/A
- Revenue
- PHUN $2,956,000.00
- MDXH $94,507,000.00
- Revenue This Year
- PHUN $3.01
- MDXH $23.51
- Revenue Next Year
- PHUN $50.72
- MDXH $17.68
- P/E Ratio
- PHUN N/A
- MDXH N/A
- Revenue Growth
- PHUN N/A
- MDXH 25.46
- 52 Week Low
- PHUN $2.22
- MDXH $1.35
- 52 Week High
- PHUN $14.60
- MDXH $3.50
- Technical
- Relative Strength Index (RSI)
- PHUN 52.92
- MDXH 52.06
- Support Level
- PHUN $3.25
- MDXH $2.09
- Resistance Level
- PHUN $3.56
- MDXH $2.22
- Average True Range (ATR)
- PHUN 0.18
- MDXH 0.10
- MACD
- PHUN 0.01
- MDXH -0.01
- Stochastic Oscillator
- PHUN 61.97
- MDXH 59.52
About PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.